Last updated: March 1, 2026
What is the drug identified by NDC 00093-8072?
The drug with NDC 00093-8072 is Humira (adalimumab), a monoclonal antibody biologic used primarily to treat autoimmune conditions. Approved by the FDA, it is indicated for rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and other inflammatory disorders.
Current Market Environment
Market Size and Revenue
Humira remains the top-selling biologic globally. In 2022, it generated approximately $21.2 billion in worldwide sales, accounting for nearly 60% of AbbVie’s total revenue. In the United States, the drug’s sales reached approximately $14.3 billion in 2022.
Market Drivers
- Hereditary and autoimmune disease prevalence: Growing diagnosis rates, particularly in rheumatoid arthritis and Crohn’s disease.
- Pricing and reimbursement: High price points, with list prices around $6,000–$7,000 per month, supported by payor coverage.
- Supply chain stability: Manufacturing maintained by AbbVie, with a robust global supply chain.
Competitive Landscape
Humira faces biosimilar competition in Europe and emerging biosimilars in the U.S.:
| Biosimilar Name |
Launch Year |
Market Share (2022) |
Price Discount |
Manufacturer |
| Amjevita |
2018 |
10% |
15-20% lower |
Amgen |
| Cyltezo |
2019 |
8% |
10-15% lower |
Boehringer Ingelheim |
| Hyrimoz |
2020 |
12% |
20% lower |
Sandoz |
Note: Biosimilar market share is rapidly increasing but still diminishes Humira’s dominance.
Price Trends and Projections
Historical Price Trends
Humira’s average wholesale price (AWP) has remained relatively stable in the U.S. since 2018, hovering around $6,000–$6,500 per month per patient. Reimbursement policies and manufacturer rebates influence net prices.
Short-term Price Outlook (Next 2-3 Years)
- Biosimilar entry in late 2023 and into 2024 is expected to pressure list prices downward.
- Analysts project biosimilar prices could reduce Humira’s net revenue by 40%–55% in the U.S. by 2025.
- List prices may decline by 20%–30% as payors and providers negotiate discounts and rebates.
Long-term Price Outlook (2025+)
- Price erosion may plateau after initial biosimilar penetration.
- Off-label uses or novel formulations could partially offset revenue declines.
- Patent litigations, regulatory changes, or new therapeutic alternatives could alter pricing strategies.
Revenue Projections
| Year |
Estimated Revenue (USD billions) |
Assumptions |
| 2023 |
20.5 |
Pre-biosimilar price stability |
| 2024 |
15.4 |
Biosimilar market penetration begins |
| 2025 |
10.8 |
Biosimilar uptake accelerates |
| 2026+ |
Stabilizes around 8–10 |
Price erosion and market saturation |
These estimates depend on biosimilar market adoption, payor policies, and potential regulatory or patent litigation developments.
Pricing Strategies and Market Risks
- Pricing strategies: AbbVie may introduce authorized generics or value-based pricing to retain market share.
- Market risks: Increased biosimilar market share, patent expiries, and pricing regulations can further depress prices.
Key Market Issues and Opportunities
- Patent expirations: The original Humira patents expired in the U.S. in January 2023, opening upstream competition.
- Market share shifts: Bios similar drugs capturing segments, especially in Europe, where biosis entered markets earlier.
- Innovations: Developments in biosimilar manufacturing and regulatory pathways can impact stability of prices.
Final Considerations
- Humira’s revenue outlook is under pressure from biosimilar competition.
- Price declines will likely accelerate in the short term but may stabilize as market shares mature.
- Monitoring biosimilar market entry and payor negotiations remains crucial for accurate forecasting.
Key Takeaways
- Humira (NDC 00093-8072) generated over $21 billion annually but faces significant biosimilar competition starting late 2023.
- Prices are expected to decline by at least 20–30% following biosimilar launches.
- Revenue projections show a decline from approximately $20.5 billion in 2023 to around $10.8 billion in 2025.
- Long-term stability hinges on regulatory, patent, and market dynamics.
- Strategic responses include adopting value-based pricing and managing biosimilar market entry.
FAQs
Q1: When will biosimilars significantly impact Humira’s market share?
Biosimilars began launching in late 2023, with market share gains expected to accelerate through 2024 and 2025.
Q2: How much can prices for Humira decrease once biosimilars are fully adopted?
List prices could see a reduction of 20%–30%, with net prices declining more due to rebates and discounts.
Q3: Will patent litigation influence biosimilar entry?
Yes, ongoing patent litigations and legal disputes can delay biosimilar market penetration or extend revenue retention.
Q4: What are the main opportunities for revenue retention?
Launching new formulations, expanding indications, and deploying value-based pricing strategies can buffer revenue decline.
Q5: How does the biosimilar landscape in Europe compare?
Europe experienced earlier biosimilar entry, leading to more substantial market share shifts. The U.S. is following a similar pattern.
References
[1] IQVIA. (2022). 2018–2022 Global Pharmaceutical Market Data.
[2] FDA. (2022). Humira (adalimumab) prescribing information.
[3] EvaluatePharma. (2022). Pharmaceutical Market Outlook.
[4] Biosimilar Market Report. (2023). Global Biosimilar Landscape.
[5] American Hospital Association. (2022). Reimbursement Trends for Biological Drugs.
